Benzinga··Vandana SinghEli Lilly's Diabetes Drug Delivers 17% Weight Loss, But Analysts Question Valuation
Eli Lilly's retatrutide shows strong weight loss results in trials, but HSBC downgrades stock citing overvaluation concerns.
LLYclinical trialweight loss